Niche NICU focus Target early engagement with NICU departments and neonatal pharmacists to discuss pagibaximab for prevention of staphylococcal sepsis in very low birth weight infants, highlighting unmet need and potential cost savings from reduced infections.

Strategic collaboration Leverage interest in additional candidates like lysostaphin and nisin as complementary assets for broad-spectrum staphylococcal control, exploring co-development or licensing partnerships with larger biopharma or academic consortia.

Clinical and regulatory trail Position near-term Phase I/II readouts and any orphan/niche indication incentives to attract partners seeking trafficking through regulatory pathways for pediatric and neonatal antibacterial products.

Cost and value case Develop a compelling cost-of-illness and hospital outcome model showing reduced NICU length of stay and lower sepsis-related morbidity to justify payer discussions and potential reimbursement strategies.

Growth through exposure Utilize the company’s focused mission and product portfolio to bio-target grant funding, academic collaborations, and venture fundraising by emphasizing specialized expertise in preventing bacterial infections in vulnerable neonatal populations.